fbpx
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Marketplaces & E-commerce
    • Ecosystem
    • Robotics
    • Investments
    • EdTech
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Startup Investing
    • Fundraising
    • Product Launching
  • MORE
    • Events
    • Startups Advice
  • Submit an Article
  • REGISTER
  • login
No Result
View All Result
No Result
View All Result
Home Health & Bio

BioMe Inc. & Yonsei Medical Center sign technology transfer contract for pathbreaking microbiome treatment

AsiaTechDaily Writer by AsiaTechDaily Writer
30 December 2021
in Health & Bio
0
BioMe is working on microbe therapeutics.

BioMe is working on microbe therapeutics.

12
SHARES
Share on FacebookShare on Twitter
Bookmark (0)

Please login to bookmark

No account yet? Register

The microbiome treatment market is receiving global attention and is rapidly emerging as a new treatment alternative for various intractable diseases. However, recent clinical trial failure reports and the limitation to identify a clear mode of action demand a careful approach. Korea-based company BioMe Inc. wants to bring in disruption with pathbreaking microbiome-based therapeutics. 

Established in November 2020 by Professor Sang Sun Yoon of the Department of Microbiology and Immunology, Yonsei University College of Medicine, BioMe Inc. has been developing a microbiome-based live biotherapeutic product (LBP). Based on the distinguished microbiology research foundation of Yonsei University College of Medicine, BioMe Inc. 

(i) understands the bacteriological characteristics of the candidate strains, 

(ii) can prove its effectiveness using animal disease models, made possible in the state-of-the-art Avison Biomedical Research Centre.

To accelerate its research & development process, the startup recently signed a technology transfer contract with Yonsei University College of Medicine. BioMe Inc. would start developing microbiome-based therapeutics with the six patents transferred from Yonsei University College of Medicine.

The technology transfer under the contract includes a total of six patents, and BioMe’s development pipeline is as follows: 

No. Development Pipeline
1 A protein derived from airway microbiome with inhibitory effects against broad-spectrum respiratory infections
2 A microbiome-derived immune enhancing protein with clear anti-cancer effect
3 A skin microbiome showing efficacy in treating atopic dermatitis
4 A consortium of commensal microbes showing efficacy in treating inflammatory bowel disease
5 Novel synbiotics system inducing butyrate synthesis

In addition to the above technology, a novel pipeline capable of degrading TMA, a risk factor for cardiovascular disease, is under development by BioMe Inc.

Beyond discovering useful strains, BioMe Inc. is building a microbiome-based system that selectively produces beneficial metabolites or degrades hazardous counterparts. This development strategy represented by “Molecule First” is implemented through the iBTSTM (integrated BioMe Technology for Screen) platform.

Recently, Kim Bu Seon, a former managing director of SK Bioscience, has been recruited to design target product profiles for candidate strains. Preclinical trials are scheduled to begin in the first half of 2022, and clinical trials will begin in 2023.

Previous Post

Indonesia’s Bukalapak names Willix Halim as interim CEO

Next Post

Singapore startup CyberHash raises $20m in Lemon-led funding

Related Posts

edit post
Etana
Health & Bio

Indonesian biotech startup Etana secures funding to bring products to SE Asia

March 27, 2023
edit post
Mitsui Koios
Health & Bio

Japan’s Mitsui backs Series B funding in US firm Koios Medical

February 28, 2023
edit post
Qritive
Featured

Healthcare AI startup Qritive nets $7.5m to expand into new markets

January 31, 2023
edit post
Holmusk
Featured

Healthtech startup Holmusk raises $45m to continue rapid expansion

January 23, 2023
edit post
HD
Featured

Thai healthcare, surgery marketplace HD raises $6m in funding

January 4, 2023
edit post
Doctor Anywhere
Health & Bio

Regional healthtech Doctor Anywhere acquires Asian Healthcare Specialists

December 31, 2022
Next Post
edit post
CyberHash

Singapore startup CyberHash raises $20m in Lemon-led funding

Discussion about this post

No Result
View All Result

Follow Us

FREE NEWSLETTER




Copyright © 2023 AsiaTechDaily.com| About Us | Seed accelerator| Terms of Use| Privacy Policy| Cookie Policy Contact : [email protected] | DMCA.com Protection Status | trusted by Wimgo

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Ecosystem
    • Marketplaces & E-commerce
    • Robotics
    • Investments
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Startup Investing
    • Fundraising
    • Product Launching
  • MORE
    • Events
    • Startups Advice
  • Submit an Article
  • Forums
  • Jobs
  • REGISTER
  • Login

Copyright © 2023 AsiaTechDaily.com| About Us | Seed accelerator| Terms of Use| Privacy Policy| Cookie Policy Contact : [email protected] | DMCA.com Protection Status | trusted by Wimgo

We hope you enjoy our content, May you please give us Feedback regarding our website!

Single Post Feedback